Endocrine Abstracts

Background and Aims: The type 1 diabetes mellitus (T1DM) remains one of the main public healthcare problems worldwide. Recent clinical studies have shown a promising stem cell role in the treatment of T1DM. We evaluated the closest therapeutic effect of autologous mesenchymal stem cell transplantation (AMSCT) on carbohydrate metabolism markers in type 1 diabetes mellitus (T1DM) patient in the honeymoon phase.

Materials and Methods: C-peptide (ng/ml), glycated hemoglobin (HbA1C,%), fructosamine (µmol/l), daily insulin dosage (Units/day) were analyzed in the 19-year- old woman (BMI 20.8 kg/m²) with 7 month history of T1DM with positive islet-cell antibodies (ICA-8.74) before and 6 weeks after AMSCT (cells were obtained from the patients iliac crest and were cultivated for 3 weeks) by intravenous infusion. The quantity of autologous mesenchymal stem cells infused was from 95-97×10⁶.

Results: AMSCT 6 weeks after led to increase C-peptide from 0.58 ng/ml to 1.72 ng/ml (normal range: 1.1-4.4 ng/ml), decrease in daily insulin dosage levels from 18 Units/day (0.38 Unit/kg) to 7 Units/day (0.15 Unit/kg) with trend to decrease HbA1c and fructosamine levels, from 8.07% to 7.26% and 320.6 µmol/l to 266.59 µmol/l (normal range: 205.0-285.0 µmol/l), respectively.

Conclusion: The AMSCT in patient with type 1 diabetes mellitus in the honeymoon phase results in an increase in the C-peptide level as well as a decrease of the daily insulin dose, with trends towards a decrease in glycated hemoglobin and fructosamine 6 weeks after transplantation.